ID

38234

Descripción

Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib; ODM derived from: https://clinicaltrials.gov/show/NCT02056080

Link

https://clinicaltrials.gov/show/NCT02056080

Palabras clave

Versiones (1)
  1. 30/9/19 30/9/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

30 de septiembre de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Neoplasm NCT02056080

Inglés

Eligibility Breast Neoplasm NCT02056080

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed diagnosis of metastatic breast cancer her2-positive phenotype (confirmed by ihc 3 + or fish positive)
Descripción

Secondary malignant neoplasm of female breast HER2 Positive Immunohistochemistry | Secondary malignant neoplasm of female breast HER2 Positive FISH Positive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0346993
UMLS CUI [1,2]
C2348909
UMLS CUI [1,3]
C0021044
UMLS CUI [2,1]
C0346993
UMLS CUI [2,2]
C2348909
UMLS CUI [2,3]
C0162789
UMLS CUI [2,4]
C1514241
older than 18 years
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
progressed to at least one prior treatment line for mbc with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes
Descripción

Prior Therapy Quantity Secondary malignant neoplasm of female breast | trastuzumab | lapatinib | Combined Modality Therapy | Chemotherapy | Hormone Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0346993
UMLS CUI [2]
C0728747
UMLS CUI [3]
C1506770
UMLS CUI [4]
C0009429
UMLS CUI [5]
C0392920
UMLS CUI [6]
C0279025
having the patient's complete medical history that contains all lines antiher2 therapy treatment
Descripción

Medical History | Targeted Therapy HER2 Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0262926
UMLS CUI [2,1]
C2985566
UMLS CUI [2,2]
C0069515
UMLS CUI [2,3]
C1265611
being a patient who initiated the combination of trastuzumab and lapatinib between january 2005 and december 2011
Descripción

Initiation Lapatinib/Trastuzumab Regimen

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1704686
UMLS CUI [1,2]
C1541246
inform the patient and get the signature of the informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
not having phenotypic classification of the tumor by ihc or fish test for her2
Descripción

Absence Immunohistochemistry Neoplasm HER2 | Absence FISH Neoplasm HER2

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0021044
UMLS CUI [1,3]
C0027651
UMLS CUI [1,4]
C0069515
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0162789
UMLS CUI [2,3]
C0027651
UMLS CUI [2,4]
C0069515
being a patient with her2-negative phenotype(fish negative or ihc in range [0-2 +] without fish)
Descripción

Patient HER2 Negative FISH Negative | Patient HER2 Negative Immunohistochemistry

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C2348908
UMLS CUI [1,3]
C0162789
UMLS CUI [1,4]
C1513916
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C2348908
UMLS CUI [2,3]
C0021044
being a patient who received the trastuzumab and/or lapatinib treatment (tl) in combination with chemotherapy
Descripción

Lapatinib/Trastuzumab Regimen | Chemotherapy | Combined Modality Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1541246
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0009429
being a patient who, since january 2012, began tl therapy for metastatic disease.
Descripción

Lapatinib/Trastuzumab Regimen Neoplasm Metastasis | Start time

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1541246
UMLS CUI [1,2]
C0027627
UMLS CUI [2]
C1301880
Volver a la parte superior de la página

Similar models

Eligibility Breast Neoplasm NCT02056080

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Secondary malignant neoplasm of female breast HER2 Positive Immunohistochemistry | Secondary malignant neoplasm of female breast HER2 Positive FISH Positive
Item
confirmed diagnosis of metastatic breast cancer her2-positive phenotype (confirmed by ihc 3 + or fish positive)
boolean
C0346993 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,3])
C0346993 (UMLS CUI [2,1])
C2348909 (UMLS CUI [2,2])
C0162789 (UMLS CUI [2,3])
C1514241 (UMLS CUI [2,4])
Age
Item
older than 18 years
boolean
C0001779 (UMLS CUI [1])
Prior Therapy Quantity Secondary malignant neoplasm of female breast | trastuzumab | lapatinib | Combined Modality Therapy | Chemotherapy | Hormone Therapy
Item
progressed to at least one prior treatment line for mbc with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])
C0009429 (UMLS CUI [4])
C0392920 (UMLS CUI [5])
C0279025 (UMLS CUI [6])
Medical History | Targeted Therapy HER2 Quantity
Item
having the patient's complete medical history that contains all lines antiher2 therapy treatment
boolean
C0262926 (UMLS CUI [1])
C2985566 (UMLS CUI [2,1])
C0069515 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Initiation Lapatinib/Trastuzumab Regimen
Item
being a patient who initiated the combination of trastuzumab and lapatinib between january 2005 and december 2011
boolean
C1704686 (UMLS CUI [1,1])
C1541246 (UMLS CUI [1,2])
Informed Consent
Item
inform the patient and get the signature of the informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Absence Immunohistochemistry Neoplasm HER2 | Absence FISH Neoplasm HER2
Item
not having phenotypic classification of the tumor by ihc or fish test for her2
boolean
C0332197 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C0027651 (UMLS CUI [1,3])
C0069515 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
C0027651 (UMLS CUI [2,3])
C0069515 (UMLS CUI [2,4])
Patient HER2 Negative FISH Negative | Patient HER2 Negative Immunohistochemistry
Item
being a patient with her2-negative phenotype(fish negative or ihc in range [0-2 +] without fish)
boolean
C0030705 (UMLS CUI [1,1])
C2348908 (UMLS CUI [1,2])
C0162789 (UMLS CUI [1,3])
C1513916 (UMLS CUI [1,4])
C0030705 (UMLS CUI [2,1])
C2348908 (UMLS CUI [2,2])
C0021044 (UMLS CUI [2,3])
Lapatinib/Trastuzumab Regimen | Chemotherapy | Combined Modality Therapy
Item
being a patient who received the trastuzumab and/or lapatinib treatment (tl) in combination with chemotherapy
boolean
C1541246 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Lapatinib/Trastuzumab Regimen Neoplasm Metastasis | Start time
Item
being a patient who, since january 2012, began tl therapy for metastatic disease.
boolean
C1541246 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial